KDR and cancer: By analyzing genetic profiles, protein expression patterns, and other proangiogenic molecular characteristics, clinicians may identify patients most likely to benefit from VEGFR-targeted therapies, thus tailoring an approach that could significantly improve treatment outcomes and resource allocation in cancer therapy.